Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer.

Sci Rep · 2022 · PMC9529905 · PMID 36192404

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In ERα-positive breast cancer patients, LLGL2 low / SLC7A5 low showed longer DFS and overall survival (OS) compared with LLGL2 high / SLC7A5 high and a positive trend of longer survival compared with the other combination groups.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.